AKT1 and familial pancreatic carcinoma: Everolimus (Evr) (Table 4) is an inhibitor of the mammalian target of rapamycin (mTOR) that modulates glucose metabolism, tube formation, cell migration, and apoptosis in pancreatic cancer cells by inhibiting the activation of the PI3K/AKT/mTOR signaling pathway.